Lindus Health secures £3.7m in seed funding from investors to scale its team
The seed round was backed by investors including Firstminute Capital, Presight Capital, and Seedcamp.
Share allotment filed at Companies House
Lindus Health runs faster end-to-end clinical trials using its proprietary technology platform and machine learning. The firm operates across the UK, US and Europe to help bring treatments for chronic conditions to patients more quickly.
Lindus Health has raised £3.7m in seed funding from a consortium of technology and healthcare investors to scale its team. The round was supported by firms including Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective, and Calm/Storm Ventures, alongside several prominent angel investors. The company was founded in March 2021 to modernise clinical trials, addressing decades of stagnation and rising costs in health research. By centralising delivery and deploying dedicated software, the firm aims to remove bottlenecks in bringing new medical treatments to market.
From the founder
"Traditional clinical research companies are dinosaurs. Taking part in a COVID vaccine trial was like stepping into a time machine. This was one of the best funded trials in history but research was done on pen and paper and participants had to go into hospital at the height of the pandemic to fill out forms. We founded Lindus Health to make it easier for patients to participate in research, and accelerate the development of new treatments."
Meri Beckwith
Co-Founder at Lindus Health
Use of funds
- 01Grow the team
Investors
firstminute
Presight Capital
Seedcamp
Hambro Perks
Amino Collective
Calm/Storm
Mehdi Ghissassi
Alex Zhavoronkov
Marc Warner
James Dacombe
Henry de Zoete
Vishal Gulati
Categories
About the company
Lindus Health
Lindus Health operates a technology platform to run faster end-to-end clinical trials.